Literature DB >> 3401051

Class-specific rheumatoid factors, DR antigens, and amyloidosis in patients with rheumatoid arthritis.

C P Maury1, A M Teppo, F Wafin, O Wegelius, C Friman, S Koskimies.   

Abstract

Class-specific rheumatoid factors (RFs) were measured by enzyme immunoassay in 59 patients with rheumatoid arthritis complicated by systemic amyloidosis (RA+A), 47 patients with rheumatoid arthritis without amyloid (RA), 106 patients with other rheumatic diseases (juvenile rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome), and 55 blood donors. The patients with RA+A were characterised by a high prevalence of RF negativity; the IgM RF concentration was raised in only 18 of the 59 patients (31%, p less than 0.001 v RA), the IgG RF concentration in 20 of 59 (34%, p less than 0.001 v RA), and the IgA RF concentration in 24 of 59 (41%, p less than 0.001 v RA). A higher prevalence of HLA-DR4 (p less than 0.001) and a lower prevalence of DR2 (p less than 0.05) were found among 48 tested patients with RA+A when compared with a control panel consisting of 500 blood donors. No significant differences in the prevalence of DR1-DR7 or B27 antigens were observed, however, between patients with RA with or without amyloid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401051      PMCID: PMC1003568          DOI: 10.1136/ard.47.7.546

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Some immunological changes in rheumatoid arthritis among patients receiving penicillamine and gold.

Authors:  E C Huskisson; H Berry
Journal:  Postgrad Med J       Date:  1974-08       Impact factor: 2.401

Review 2.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

Review 3.  Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

4.  Physiology and pathology of rheumatoid factors.

Authors:  D A Carson; J L Pasquali; C D Tsoukas; S Fong; S F Slovin; S K Lawrance; L Slaughter; J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1981

5.  Seronegative rheumatoid arthritis. A distinct immunogenetic disease?

Authors:  G S Alarcón; W J Koopman; R T Acton; B O Barger
Journal:  Arthritis Rheum       Date:  1982-05

6.  The induction of a rheumatoid factor-like substance in rabbits.

Authors:  J L ABRUZZO; C L CHRISTIAN
Journal:  J Exp Med       Date:  1961-11-01       Impact factor: 14.307

7.  Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up.

Authors:  R K Jacoby; M I Jayson; J A Cosh
Journal:  Br Med J       Date:  1973-04-14

8.  HLA and rheumatoid arthritis: a combined analysis of 440 British patients.

Authors:  D Jaraquemada; W Ollier; J Awad; A Young; A Silman; I M Roitt; M Corbett; F Hay; J A Cosh; R N Maini
Journal:  Ann Rheum Dis       Date:  1986-08       Impact factor: 19.103

9.  Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

Authors:  P Stastny
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

10.  Prospective study of early rheumatoid arthritis. II. Association of rheumatoid factor isotypes with fluctuations in disease activity.

Authors:  R H Withrington; I Teitsson; H Valdimarsson; M H Seifert
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

View more
  2 in total

1.  HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis and amyloidosis.

Authors:  S Tiitinen; K Kaarela; A Filipowicz-Sosnowska; B Maczynska-Rusiniak; K Lehtinen; M Leirisalo-Repo; L Paimela; S Koskimies
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

2.  Juvenile rheumatoid arthritis and renal amyloidosis (case report).

Authors:  S Kavukçu; M Türkmen; O Saatçi; G Başdemir; Z Gülay; N T Cevik
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.